NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in Adaptimmune Therapeutics plc (“Adaptimmune” or the “Company”) (NASDAQ: ADAP). Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether Adaptimmune and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On September 9, 2022, Adaptimmune issued a press release announcing new data from its Phase 1 SURPASS study of the cancer drug ADP-A2M4CD8 in patients with solid tumors. Among other findings, the press release revealed that “[a]many adverse events (AEs) of particular interest: 32 people (73%) had cytokine release syndrome (CRS); most events were low grade and resolved (~86% ? Grade 2). Eleven subjects (25%) had cytopenia (Grade ? 3) 4 weeks after treatment. Three individuals (7%) had ADP-A2M4CD8-related immune effector cell-associated neurotoxicity syndrome (ICANS).” The press release further states: “[t]Here, 2 investigator-related deaths have been reported. A 60-year-old woman with ovarian cancer and a large tumor burden in the lungs died of pneumonia and CRS” and “a 71-year-old man with a history of esophageal adenocarcinoma and chronic anemia died of bone marrow failure.”

As a result of this news, Adaptimmune’s stock price fell $0.12 per share, or 5.88%, to close at $1.92 per share on September 9, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later,…